Physician profile
Winston Tan
NPI 1245229772
$1,597.02
in general payments reported to CMS, 2019-2025
22 companies · $614 in 2025
The $614 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2022: $143 · 2023: $351 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851 · Education: $84.99 · Travel and Lodging: $29.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.67 |
| Education | $84.99 |
| Travel and Lodging | $29.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $264.75 | 2025 | |
| Janssen Biotech, INC. | $146.21 | 2025 | Rybrevant, Carvykti |
| Janssen Scientific Affairs, LLC | $135.73 | 2023 | Balversa, Pipeline, Erleada |
| Exelixis INC. | $126.19 | 2019-2023 | |
| Eisai INC. | $123.31 | 2025 | |
| Genentech USA, INC. | $121.01 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.41 | 2019 | |
| Amgen INC. | $111.85 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $100.98 | 2019 | |
| Gilead Sciences, INC. | $100.67 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.45 | 2022 | |
| Sandoz INC. | $80.00 | 2025 | |
| Merck Sharp & Dohme LLC | $43.51 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $29.95 | 2023 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Winston Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.